Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1958 2
1963 9
1964 16
1965 12
1975 1
1976 3
1977 7
1978 16
1979 5
1980 2
1981 11
1982 7
1983 12
1984 11
1985 17
1986 17
1987 34
1988 17
1989 24
1990 11
1991 9
1992 17
1993 5
1994 6
1995 13
1996 11
1997 13
1998 21
1999 16
2000 19
2001 19
2002 17
2003 14
2004 18
2005 16
2006 16
2007 18
2008 24
2009 21
2010 24
2011 29
2012 33
2013 28
2014 38
2015 39
2016 30
2017 35
2018 36
2019 44
2020 65
2021 45
2022 40
2023 52
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

1,007 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for ambroxol
Search for ambroxan instead (2 results)
Ambroxol in the 21st century: pharmacological and clinical update.
Malerba M, Ragnoli B. Malerba M, et al. Expert Opin Drug Metab Toxicol. 2008 Aug;4(8):1119-29. doi: 10.1517/17425255.4.8.1119. Expert Opin Drug Metab Toxicol. 2008. PMID: 18680446 Review.
Therefore, ambroxol's indication is 'secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport'. ...The anaesthetic effect is a new pharmacological action that could be beneficial in the manage …
Therefore, ambroxol's indication is 'secretolytic therapy in acute and chronic bronchopulmonary diseases associated with abnormal muc …
Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.
Mullin S, Smith L, Lee K, D'Souza G, Woodgate P, Elflein J, Hällqvist J, Toffoli M, Streeter A, Hosking J, Heywood WE, Khengar R, Campbell P, Hehir J, Cable S, Mills K, Zetterberg H, Limousin P, Libri V, Foltynie T, Schapira AHV. Mullin S, et al. JAMA Neurol. 2020 Apr 1;77(4):427-434. doi: 10.1001/jamaneurol.2019.4611. JAMA Neurol. 2020. PMID: 31930374 Free PMC article. Clinical Trial.
These observations support a potential role for ambroxol therapy in modifying a relevant pathogenetic pathway in PD. ...These changes were observed in patients with and without GBA1 mutations. CONCLUSIONS AND RELEVANCE: The study results suggest that ambroxol therap …
These observations support a potential role for ambroxol therapy in modifying a relevant pathogenetic pathway in PD. ...These changes …
Ambroxol for neuropathic pain: hiding in plain sight?
Russo MA, Baron R, Dickenson AH, Kern KU, Santarelli DM. Russo MA, et al. Pain. 2023 Jan 1;164(1):3-13. doi: 10.1097/j.pain.0000000000002693. Epub 2022 May 17. Pain. 2023. PMID: 35580314 Review.
Ambroxol is a multifaceted drug with primarily mucoactive and secretolytic actions, along with anti-inflammatory, antioxidant, and local anaesthetic properties. ...With its well-established safety profile, extensive preclinical and clinical drug data, and early evidence of
Ambroxol is a multifaceted drug with primarily mucoactive and secretolytic actions, along with anti-inflammatory, antioxidant, and lo
Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
Silveira CRA, MacKinley J, Coleman K, Li Z, Finger E, Bartha R, Morrow SA, Wells J, Borrie M, Tirona RG, Rupar CA, Zou G, Hegele RA, Mahuran D, MacDonald P, Jenkins ME, Jog M, Pasternak SH. Silveira CRA, et al. BMC Neurol. 2019 Feb 9;19(1):20. doi: 10.1186/s12883-019-1252-3. BMC Neurol. 2019. PMID: 30738426 Free PMC article. Clinical Trial.
The aims of this trial are to determine if Ambroxol is safe and well-tolerated by individuals with PDD and if Ambroxol affects cognitive, biochemical, and neuroimaging measures. ...DISCUSSION: If found effective and safe, Ambroxol will be one of the first dis …
The aims of this trial are to determine if Ambroxol is safe and well-tolerated by individuals with PDD and if Ambroxol affects …
[Ambroxol].
Akkoca Yildiz O. Akkoca Yildiz O. Tuberk Toraks. 2006;54 Suppl 1:3-14. Tuberk Toraks. 2006. PMID: 17089236 Review. Turkish. No abstract available.
Polypharmacology of ambroxol in the treatment of COVID-19.
Wang Z, Yang M, Chen X, Xiao R, Dong Y, Chu M, Song G, Wang Y. Wang Z, et al. Biosci Rep. 2023 Feb 27;43(2):BSR20221927. doi: 10.1042/BSR20221927. Biosci Rep. 2023. PMID: 36651548 Free PMC article.
Therefore, we focused on the mechanism of action of ambroxol in COVID-19 treatment. In vitro and in silico screening revealed that ambroxol may impede cell entry of SARS-CoV-2 by binding to neuropilin-1. ...Collectively, these results suggested that ambroxol
Therefore, we focused on the mechanism of action of ambroxol in COVID-19 treatment. In vitro and in silico screening revealed that …
Safety of ambroxol in the treatment of airway diseases in adult patients.
Cazan D, Klimek L, Sperl A, Plomer M, Kölsch S. Cazan D, et al. Expert Opin Drug Saf. 2018 Dec;17(12):1211-1224. doi: 10.1080/14740338.2018.1533954. Epub 2018 Nov 22. Expert Opin Drug Saf. 2018. PMID: 30372367 Review.
Areas covered: Here, we evaluate the clinical safety of ambroxol and provide an expert opinion on the benefit-risk balance of ambroxol in the treatment of adult patients with bronchopulmonary diseases. The evidence for this review is derived from clinical trials of …
Areas covered: Here, we evaluate the clinical safety of ambroxol and provide an expert opinion on the benefit-risk balance of ambr
Ambroxol: a CNS drug?
Weiser T. Weiser T. CNS Neurosci Ther. 2008 Spring;14(1):17-24. doi: 10.1111/j.1527-3458.2007.00032.x. CNS Neurosci Ther. 2008. PMID: 18482096 Free PMC article. Review.
For almost three decades ambroxol has been used in the therapy of airway diseases. In 2002, ambroxol lozenges were marketed for the treatment of sore throat making use of its local anesthetic effect. ...The analgesic effects of ambroxol by either systemic adm …
For almost three decades ambroxol has been used in the therapy of airway diseases. In 2002, ambroxol lozenges were marketed fo …
Enhancement of lung levels of antibiotics by ambroxol and bromhexine.
Deretic V, Timmins GS. Deretic V, et al. Expert Opin Drug Metab Toxicol. 2019 Mar;15(3):213-218. doi: 10.1080/17425255.2019.1578748. Epub 2019 Feb 7. Expert Opin Drug Metab Toxicol. 2019. PMID: 30721101 Free PMC article. Review.
In most cases, the increased levels are only modest and are insufficient to overcome high-level resistance against that same antibiotic class, and so co-treatment with ambroxol is unlikely to alter clinical outcomes. Additionally, for most antibiotics there is no evidence …
In most cases, the increased levels are only modest and are insufficient to overcome high-level resistance against that same antibiotic clas …
Use of Ambroxol as Therapy for Gaucher Disease.
Zhan X, Zhang H, Maegawa GHB, Wang Y, Gao X, Wang D, Li J. Zhan X, et al. JAMA Netw Open. 2023 Jun 1;6(6):e2319364. doi: 10.1001/jamanetworkopen.2023.19364. JAMA Netw Open. 2023. PMID: 37342037 Free PMC article.
Data analyses were performed from May 2015 to November 2022. INTERVENTION: An escalating dose of oral ambroxol (mean [SD] dose, 12.7 [3.9] mg/kg/d). MAIN OUTCOMES AND MEASURES: Patients with GD receiving ambroxol were followed up in a genetic metabolism center. ...T …
Data analyses were performed from May 2015 to November 2022. INTERVENTION: An escalating dose of oral ambroxol (mean [SD] dose, 12.7 …
1,007 results